Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline ...

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...

Fact checked by Jennifer Klump Although respiratory syncytial virus (RSV) is often associated with children, adults can also ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Moderna (MRNA) stock drops even after beating Q2 2025 forecasts, as it lowered the top end of the revenue outlook due to ...

Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...

Q2 2025 Earnings Call Transcript August 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.13, ...

Vaccines are the best way to protect yourself from those illnesses, as well as from viruses such as RSV, influenza, and COVID ...

The company reported a net loss of $825 million for the quarter. Additionally, Moderna announced a $300 million reduction at the high end of their 2025 projected revenue range due to a timing shift of ...

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the use of its respiratory syncytial virus (RSV) vaccine to adults under the age ...

Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...